Semaglutide and Your Heart: What the SELECT Trial Means for 2026 Coverage

For years, semaglutide has been known mainly as a weight-loss medication. The conversation around it centered on the number on the scale, on clothing fitting differently, on energy levels returning. But a landmark study called SELECT changed that conversation entirely. The findings, released in 2023 and still rippling through the medical community, showed that semaglutide does something many people did not expect. It protects the heart.

The SELECT trial followed more than 17,000 adults over five years. Every participant was over 45 years old, had established cardiovascular disease, and lived with obesity or overweight, but none had diabetes. The results were striking. Those who took semaglutide reduced their risk of heart attack, stroke, and cardiovascular death by 20 percent compared to those on placebo. Twenty percent. That is not a marginal gain. That is a meaningful reduction in events that change lives and end them.

The mechanism behind this benefit is not fully understood yet, but researchers have clues. Semaglutide works by mimicking a hormone called GLP-1, which regulates appetite and blood sugar. Beyond those effects, the medication appears to reduce inflammation in blood vessels, lower blood pressure, and improve lipid profiles. It seems the drug acts on the cardiovascular system through multiple pathways simultaneously, which explains why the benefits showed up even in people whose weight loss was considered modest.

What makes this especially relevant for 2026 is Medicare.

Until recently, Medicare coverage for semaglutide was limited to people with type 2 diabetes. That created a significant barrier for the millions of older Americans who have cardiovascular disease and obesity but do not have diabetes. They could not access the medication through Medicare, and at list prices, the cost was prohibitive for most.

That changed with the passage of new coverage rules. Starting in 2026, Medicare Part D will cover semaglutide for beneficiaries with established cardiovascular disease, regardless of diabetes status. The decision was driven directly by the SELECT trial data. CMS reviewed the evidence, determined that the cardiovascular benefit was well-established, and expanded the coverage determination accordingly.

This is a policy shift that will reach many people. Cardiovascular disease remains the leading cause of death in the United States. Obesity affects roughly 42 percent of American adults, and the overlap between obesity and heart disease is substantial. For someone who has already had a cardiac event and is trying to prevent another, having access to a medication that demonstrably lowers that risk is not a luxury. It is a clinical tool that should be available.

Of course, coverage expansion does not mean automatic access. There are still steps involved. Patients need a prescription from a clinician who determines they meet the criteria. Prior authorization may apply depending on the specific Medicare plan. And like any medication, semaglutide comes with potential side effects, most commonly gastrointestinal symptoms like nausea, especially during the dose escalation period. These effects tend to diminish over time, but they are real and deserve discussion with a healthcare provider.

There is also an important distinction worth making. Coverage under Medicare Part D means the medication is available through pharmacy benefit plans, not necessarily administered in a hospital setting. The way a patient receives the medication depends on whether their plan covers it under Part D versus Part B, and the specifics matter for out-of-pocket costs.

For people navigating this landscape, organizing information becomes essential. Tracking which medications a person is taking, what their cardiovascular history looks like, and what questions they want to ask their doctor can make the difference between a productive appointment and a frustrating one.

The Ozempro app was built for exactly this kind of practical support. If you are trying to understand whether semaglutide makes sense for your situation, clicking here to take a short quiz can help clarify the options and what to discuss with your provider next.

Beyond medication, the SELECT trial reinforces something that cardiologists have long advocated. Weight management is not cosmetic. It is a core component of heart health. Every pound lost tends to reduce blood pressure and improve lipid markers. Semaglutide does not replace diet and exercise, but it creates a biological shift that makes those changes more sustainable for many people. The medication handles the appetite regulation that has long made lasting weight loss so difficult.

The conversation between a patient and their cardiologist will look different now. Five years ago, bringing up weight-loss medication in a cardiac context might have felt off-topic. Today, with evidence like SELECT, it is a legitimate part of the discussion. Clinicians are increasingly comfortable incorporating these tools into comprehensive cardiovascular care plans that include lifestyle changes, monitoring, and when appropriate, pharmacological support.

One thing to keep in mind is that the 2026 coverage expansion is still rolling out. Plan formularies are being updated, and the specifics of eligibility criteria are being finalized. Patients who think they might qualify should check with their Medicare plan administrator and ask their doctor whether they meet the current clinical criteria.

The heart health landscape is shifting. Medications that once seemed focused entirely on weight have revealed broader benefits that reach into some of the most serious health conditions Americans face. Making those medications more accessible through expanded Medicare coverage is a step toward treating cardiovascular disease more comprehensively. Whether that path is right for any individual is a decision to make with a doctor who knows their history and their goals.

References

• EMA — Ozempic (semaglutida), EPAR
• Wilding et al., STEP 1 — NEJM (2021)
• Lincoff et al., SELECT — NEJM (2023)